{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:02:46Z","timestamp":1792274566164,"version":"4.4.0"},"reference-count":38,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T00:00:00Z","timestamp":1644278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb (United States)","doi-asserted-by":"publisher","award":["not applicable"],"award-info":[{"award-number":["not applicable"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Anemia is the most common form of cytopenia in patients with myelodysplastic syndromes (MDS), who require chronic red blood cell transfusions and may present high serum ferritin (SF) levels as a result of iron overload. To better understand the potential effects of high SF levels, we conducted a systematic literature review (SLR) to identify evidence on the relationship between SF levels and clinical, economic, or humanistic outcomes in adult patients with MDS. Of 267 references identified, 21 were included. No studies assessing SF levels and their relationship with humanistic or economic outcomes were identified. Increased SF levels were an indicator of worse overall survival and other worsened outcomes; however, the association was not consistently significant. SF levels were a significant prognostic factor for relapse incidence of MDS and showed a significant positive correlation with number of blood units transfused but were not associated with progression to acute myeloid leukemia or the time to transformation. Higher SF levels were also an indicator of a lower likelihood of leukemia-free survival, relapse-free survival, and event-free survival. The SLR suggests that SF levels are associated with clinical outcomes in MDS, with higher levels correlated with number of blood units transfused, frequently indicating worse outcomes.<\/jats:p>","DOI":"10.3390\/jcm11030895","type":"journal-article","created":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T23:37:48Z","timestamp":1644363468000},"page":"895","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A Systematic Literature Review of the Relationship between Serum Ferritin and Outcomes in Myelodysplastic Syndromes"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9238-5734","authenticated-orcid":false,"given":"Esther Natalie","family":"Oliva","sequence":"first","affiliation":[{"name":"Hematology Unit, Grande Ospedale Metropolitano Bianchi Melacrino Morelli, 89124 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystal","family":"Huey","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ 08540, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohan","family":"Deshpande","sequence":"additional","affiliation":[{"name":"Evidera, London W6 8BJ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Turner","sequence":"additional","affiliation":[{"name":"Evidera, Waltham, MA 02451, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhura","family":"Chitnis","sequence":"additional","affiliation":[{"name":"Evidera, Waltham, MA 02451, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Schiller","sequence":"additional","affiliation":[{"name":"Evidera, Waltham, MA 02451, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Tang","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ 08540, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aylin","family":"Yucel","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ 08540, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Hughes","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ 08540, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5975-1309","authenticated-orcid":false,"given":"Farrukh","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Haematology, Whittington Health NHS Foundation Trust, London N19 5NF, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s11899-015-0269-y","article-title":"Incidence and burden of the myelodysplastic syndromes","volume":"10","author":"Cogle","year":"2015","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(13)61901-7","article-title":"Myelodysplastic syndromes","volume":"383","author":"Ades","year":"2014","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.3109\/10428194.2013.878934","article-title":"Initial transfusion intensity predicts survival in myelodysplastic syndrome","volume":"55","author":"Chan","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"394295","DOI":"10.1155\/2013\/394295","article-title":"Ineffective erythropoiesis in \u00df-Thalassemia","volume":"2013","author":"Ribeil","year":"2013","journal-title":"Sci. World J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.critrevonc.2014.01.006","article-title":"Iron overload and chelation therapy in myelodysplastic syndromes","volume":"91","author":"Temraz","year":"2014","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.mric.2010.08.014","article-title":"Magnetic resonance imaging quantification of liver iron","volume":"18","author":"Sirlin","year":"2010","journal-title":"Magn. Reson. Imaging Clin. N. Am."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e24959","DOI":"10.5812\/ircmj.17(4)2015.24959","article-title":"Serum ferritin levels correlation with heart and liver MRI and LIC in patients with transfusion-dependent thalassemia","volume":"17","author":"Majd","year":"2015","journal-title":"Iran Red Crescent Med. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMct1004810","article-title":"Iron-chelating therapy for transfusional iron overload","volume":"364","author":"Brittenham","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1182\/blood.V112.11.640.640","article-title":"Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome","volume":"112","author":"Sanz","year":"2008","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration","volume":"151","author":"Liberati","year":"2009","journal-title":"Ann. Int. Med."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Moher, D., Liberati, A., Tetzlaff, J., and Altman, D.G. (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med., 6.","DOI":"10.1371\/journal.pmed.1000097"},{"key":"ref_12","unstructured":"Higgins, J.P., and Green, S. (2011). Cochrane Handbook for Systematic Reviews of Interventions, version 5.1.0, The Cochrane Collaboration."},{"key":"ref_13","unstructured":"National Institute for Health and Care Excellence (NICE) (2022, February 01). NICE Guidance PMG9: Guide to the Methods of Technology Appraisal. Available online: https:\/\/www.nice.org.uk\/process\/pmg9\/chapter\/foreword."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann. Int. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.transci.2013.04.025","article-title":"Adverse impact of hyperferritinemia and transfusion dependency on treatment success in myelodysplastic syndrome","volume":"48","author":"Cakar","year":"2013","journal-title":"Transfus. Apher. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.leukres.2009.06.033","article-title":"Impact of transfusion dependency on survival in patients with early myelodysplastic syndrome without excess of blasts","volume":"33","author":"Cermak","year":"2009","journal-title":"Leuk. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1080\/10428194.2019.1594215","article-title":"A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation","volume":"60","author":"Cremers","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1080\/10428194.2018.1540783","article-title":"Chronic myelomonocytic leukemia treated with 5-azacytidine-results from the Hellenic 5-Azacytidine Registry: Proposal of a new risk stratification system","volume":"60","author":"Diamantopoulos","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/jcpt.12348","article-title":"Impact of medication adherence on the effectiveness of deferasirox for the treatment of transfusional iron overload in myelodysplastic syndrome","volume":"41","year":"2016","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1445-5994.2011.02443.x","article-title":"Myelodysplasia in the Wellington region 2002-2007: Disease incidence and treatment patterns","volume":"41","author":"Irwin","year":"2011","journal-title":"Intern. Med. J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijge.2017.06.001","article-title":"Verification of survival predictors in elderly patients with myelodysplastic syndrome from outpatient clinical practice","volume":"12","author":"Kadlckova","year":"2018","journal-title":"Int. J. Gerontol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s12185-019-02710-1","article-title":"Serum ferritin levels at diagnosis predict prognosis in patients with low blast count myelodysplastic syndromes","volume":"110","author":"Kawabata","year":"2019","journal-title":"Int. J. Hematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s12185-012-1048-3","article-title":"Prognostic significance of serum ferritin level at diagnosis in myelodysplastic syndrome","volume":"95","author":"Kikuchi","year":"2012","journal-title":"Int. J. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1159\/000345428","article-title":"Serum ferritin is an independent prognostic factor in Chinese with myelodysplastic syndromes classified as IPSS Intermediate-1","volume":"129","author":"Li","year":"2013","journal-title":"Acta. Haematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1080\/10245332.2015.1101964","article-title":"Hemochromatosis gene mutations may affect the survival of patients with myelodysplastic syndrome","volume":"21","author":"Lucijanic","year":"2016","journal-title":"Hematology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/j.bbmt.2014.06.022","article-title":"Cytogenetics, donor type, and use of hypomethylating agents in myelodysplastic syndrome with allogeneic stem cell transplantation","volume":"20","author":"Oran","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_27","first-page":"945","article-title":"Clinical implication of serum ferritin level at diagnosis in patients with myelodysplastic syndromes","volume":"2","author":"Osanai","year":"2018","journal-title":"Hemasphere"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.leukres.2011.07.007","article-title":"Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS","volume":"35","author":"Park","year":"2011","journal-title":"Leuk. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/leu.2010.105","article-title":"WHO-defined \u2018myelodysplastic syndrome with isolated del(5q)\u2019 in 88 consecutive patients: Survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations","volume":"24","author":"Patnaik","year":"2010","journal-title":"Leukemia"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/ejh.13353","article-title":"Allogeneic stem cell transplant in myelodysplastic syndrome-factors impacting survival","volume":"104","author":"Prem","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"103","DOI":"10.17925\/EOH.2016.12.02.103","article-title":"Transient elastography for the detection of hepatic iron overload in patients with myelodysplastic syndrome","volume":"12","author":"Risum","year":"2016","journal-title":"Eur. Oncol. Haematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.tracli.2019.07.005","article-title":"In myelodysplastic syndrome cases, what should be the level of ferritin which has prognostic value?","volume":"26","author":"Akinci","year":"2019","journal-title":"Trans. Clin. Biol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/annonc\/mdp258","article-title":"Comorbidity as prognostic variable in MDS: Comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS study group","volume":"21","author":"Sperr","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"633","DOI":"10.17219\/acem\/62397","article-title":"Red blood cell transfusion dependency and hyperferritinemia are associated with impaired survival in patients diagnosed with myelodysplastic syndromes: Results from the first Polish MDS-PALG Registry","volume":"25","author":"Madry","year":"2016","journal-title":"Adv. Clin. Exp. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.leukres.2017.11.005","article-title":"Iron chelation therapy in lower IPSS risk myelodysplastic syndromes; Which subtypes benefit?","volume":"64","author":"Wong","year":"2018","journal-title":"Leuk. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1179\/102453309X12473408860424","article-title":"Socio-psychological impact of infused iron chelation therapy with deferoxamine in metropolitan France: ISOSFER study results","volume":"14","author":"Thuret","year":"2009","journal-title":"Hematology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1136\/bmjspcare-2014-000726","article-title":"Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: A prospective study to assess the impact of iron chelation therapy","volume":"6","author":"Efficace","year":"2016","journal-title":"BMJ Support Palliat. Care."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/ajh.22001","article-title":"Predicted costs of iron-chelators in myelodysplastic syndromes: A 10-year analysis based on actual prevalence and red cell transfusion rates","volume":"86","author":"Durairaj","year":"2011","journal-title":"Am. J. Hematol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/3\/895\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:16:11Z","timestamp":1760134571000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/3\/895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,8]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["jcm11030895"],"URL":"https:\/\/doi.org\/10.3390\/jcm11030895","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,8]]}}}